SELLAS Life Sciences Group, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
SELLAS Life Sciences Group, Inc. (SLS) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$3.64 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-04-13.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-04-13
- SELLAS Life Sciences Group, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $1.53M, a 84.40% decline year-over-year.
- SELLAS Life Sciences Group, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$5.16M, a 204.77% decline year-over-year.
- SELLAS Life Sciences Group, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$9.57M.
- SELLAS Life Sciences Group, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was $9.56M, a 91.95% increase year-over-year.
- SELLAS Life Sciences Group, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$3.64M, a 179.80% decline from fiscal 2016.
- SELLAS Life Sciences Group, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $4.57M, a 24.92% decline from fiscal 2015.
- SELLAS Life Sciences Group, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $6.08M.
- SELLAS Life Sciences Group, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$24.14M, a 261.13% decline from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 102 month | Cash and Cash Equivalents, Period Increase (Decrease) 105 month | Cash and Cash Equivalents, Period Increase (Decrease) 108 month | Cash and Cash Equivalents, Period Increase (Decrease) 111 month | Cash and Cash Equivalents, Period Increase (Decrease) 114 month | Cash and Cash Equivalents, Period Increase (Decrease) 117 month | Cash and Cash Equivalents, Period Increase (Decrease) 120 month | Cash and Cash Equivalents, Period Increase (Decrease) 123 month | Cash and Cash Equivalents, Period Increase (Decrease) 126 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-13 | -$3.63M derived: sum of 2 quarters · filed 2018-04-13 | -$13.20M derived: sum of 3 quarters · filed 2018-04-13 | -$3.64M 10-K · filed 2018-04-13 | ||||||||||
| 2017-09-30 | -$5.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$14.73M derived: sum of 2 quarters · filed 2017-11-09 | -$5.17M 10-Q · filed 2017-11-09 | $4.61M derived: sum of 4 quarters · filed 2018-04-13 | ||||||||||
| 2017-06-30 | -$9.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$10.00K 10-Q · filed 2017-08-14 | $9.77M derived: sum of 3 quarters · filed 2018-04-13 | $14.70M derived: sum of 4 quarters · filed 2018-04-13 | ||||||||||
| 2017-03-31 | $9.56M 10-Q · filed 2017-05-10 | $19.34M derived: sum of 2 quarters · filed 2018-04-13 | $24.26M derived: sum of 3 quarters · filed 2018-04-13 | $9.14M derived: sum of 4 quarters · filed 2018-04-13 | ||||||||||
| 2016-12-31 | $9.78M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-13 | $14.71M derived: sum of 2 quarters · filed 2018-04-13 | -$414.00K derived: sum of 3 quarters · filed 2018-04-13 | $4.57M 10-K · filed 2018-04-13 | -$11.65M 10-K · filed 2017-03-15 | |||||||||
| 2016-09-30 | $4.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$10.20M derived: sum of 2 quarters · filed 2017-11-09 | -$5.22M 10-Q · filed 2017-11-09 | -$10.30M derived: sum of 4 quarters · filed 2017-11-09 | ||||||||||
| 2016-06-30 | -$15.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$10.14M 10-Q · filed 2017-08-14 | -$15.22M derived: sum of 3 quarters · filed 2017-08-14 | -$25.69M derived: sum of 4 quarters · filed 2017-08-14 | ||||||||||
| 2016-03-31 | $4.98M 10-Q · filed 2017-05-10 | -$103.00K derived: sum of 2 quarters · filed 2017-05-10 | -$10.57M derived: sum of 3 quarters · filed 2017-05-10 | -$18.15M derived: sum of 4 quarters · filed 2017-05-10 | ||||||||||
| 2015-12-31 | -$5.08M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$15.55M derived: sum of 2 quarters · filed 2017-03-15 | -$23.13M derived: sum of 3 quarters · filed 2017-03-15 | $6.08M 10-K · filed 2017-03-15 | ||||||||||
| 2015-09-30 | -$10.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$18.05M derived: sum of 2 quarters · filed 2016-11-09 | $11.16M 10-Q · filed 2016-11-09 | $10.16M derived: sum of 4 quarters · filed 2017-03-15 | ||||||||||
| 2015-06-30 | -$7.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $21.63M 10-Q · filed 2016-08-09 | $20.63M derived: sum of 3 quarters · filed 2017-03-15 | $6.12M derived: sum of 4 quarters · filed 2017-03-15 | ||||||||||
| 2015-03-31 | $29.21M 10-Q · filed 2016-05-10 | $28.21M derived: sum of 2 quarters · filed 2017-03-15 | $13.70M derived: sum of 3 quarters · filed 2017-03-15 | $433.00K derived: sum of 4 quarters · filed 2017-03-15 | ||||||||||
| 2014-12-31 | -$997.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$15.51M derived: sum of 2 quarters · filed 2017-03-15 | -$28.78M derived: sum of 3 quarters · filed 2017-03-15 | -$24.14M 10-K · filed 2017-03-15 | ||||||||||
| 2014-09-30 | -$14.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$27.78M derived: sum of 2 quarters · filed 2015-11-09 | -$23.14M 10-Q · filed 2015-11-09 | -$26.75M derived: sum of 4 quarters · filed 2016-04-15 | ||||||||||
| 2014-06-30 | -$13.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$8.63M 10-Q · filed 2015-08-06 | -$12.23M derived: sum of 3 quarters · filed 2016-04-15 | $18.24M derived: sum of 4 quarters · filed 2016-04-15 | ||||||||||
| 2014-03-31 | $4.64M 10-Q · filed 2015-05-07 | $1.03M derived: sum of 2 quarters · filed 2016-04-15 | $31.51M derived: sum of 3 quarters · filed 2016-04-15 | $34.95M derived: sum of 4 quarters · filed 2016-04-15 | ||||||||||
| 2013-12-31 | -$3.61M derived: 10-K/A 12 month − 10-Q 9 month · filed 2016-04-15 | $26.87M derived: sum of 2 quarters · filed 2016-04-15 | $30.31M derived: sum of 3 quarters · filed 2016-04-15 | $14.98M 10-K/A · filed 2016-04-15 | ||||||||||
| 2013-09-30 | $30.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $33.91M derived: sum of 2 quarters · filed 2014-11-05 | $18.59M 10-Q · filed 2014-11-05 | $35.97M derived: sum of 4 quarters · filed 2015-12-04 | ||||||||||
| 2013-06-30 | $3.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$11.89M 10-Q · filed 2014-08-11 | $5.50M derived: sum of 3 quarters · filed 2015-12-04 | $1.69M derived: sum of 4 quarters · filed 2015-12-04 | $20.92M 10-Q · filed 2013-08-09 | |||||||||
| 2013-03-31 | -$15.33M 10-Q · filed 2014-05-06 | $2.06M derived: sum of 2 quarters · filed 2015-12-04 | -$1.75M derived: sum of 3 quarters · filed 2015-12-04 | $8.78M derived: sum of 4 quarters · filed 2015-12-04 | $17.48M 10-Q · filed 2013-05-09 | |||||||||
| 2012-12-31 | $17.38M derived: 8-K 12 month − 10-Q/A 9 month · filed 2015-12-04 | $13.58M derived: sum of 2 quarters · filed 2015-12-04 | $24.11M derived: sum of 3 quarters · filed 2015-12-04 | $21.37M 8-K · filed 2015-12-04 | $32.81M 10-K · filed 2013-03-12 | |||||||||
| 2012-09-30 | -$3.81M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2013-11-07 | $6.72M derived: sum of 2 quarters · filed 2013-11-07 | $3.99M 10-Q/A · filed 2013-11-07 | -$270.00K derived: sum of 4 quarters · filed 2014-03-17 | $15.42M 10-Q · filed 2012-11-13 | |||||||||
| 2012-06-30 | $10.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $7.79M 10-Q · filed 2013-08-09 | $3.54M derived: sum of 3 quarters · filed 2014-03-17 | $1.29M derived: sum of 4 quarters · filed 2014-03-17 | $19.23M 10-Q · filed 2012-08-14 | |||||||||
| 2012-03-31 | -$2.73M 10-Q · filed 2013-05-09 | -$6.99M derived: sum of 2 quarters · filed 2014-03-17 | -$9.23M derived: sum of 3 quarters · filed 2014-03-17 | -$2.41M derived: sum of 4 quarters · filed 2014-03-17 | $8.70M 10-Q · filed 2012-05-14 | |||||||||
| 2011-12-31 | -$4.26M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | -$6.50M derived: sum of 2 quarters · filed 2014-03-17 | $318.00K derived: sum of 3 quarters · filed 2014-03-17 | $4.54M 10-K · filed 2014-03-17 | $11.43M 10-K · filed 2012-03-28 | |||||||||
| 2011-09-30 | -$2.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-13 | $4.58M derived: sum of 2 quarters · filed 2012-11-13 | $8.80M 10-Q · filed 2012-11-13 | $12.86M derived: sum of 4 quarters · filed 2012-11-13 | $15.69M 10-Q · filed 2011-11-14 | |||||||||
| 2011-06-30 | $6.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | $11.04M 10-Q · filed 2012-08-14 | $15.10M derived: sum of 3 quarters · filed 2012-08-14 | $12.84M derived: sum of 4 quarters · filed 2012-08-14 | $17.93M 10-Q/A · filed 2011-10-28 | |||||||||
| 2011-03-31 | $4.22M 10-Q · filed 2012-05-14 | $8.28M derived: sum of 2 quarters · filed 2012-05-14 | $6.02M derived: sum of 3 quarters · filed 2012-05-14 | |||||||||||
| 2010-12-31 | $4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-28 | $1.80M derived: sum of 2 quarters · filed 2012-03-28 | $1.21M 10-K · filed 2012-03-28 | |||||||||||
| 2010-09-30 | -$2.26M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-14 | -$2.85M 10-Q · filed 2011-11-14 | ||||||||||||
| 2010-06-30 | -$591.00K 10-Q/A · filed 2011-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |